Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report
Progyny (NASDAQ: PGNY), a leader in women's health and family building solutions, has secured a new $200 million revolving credit facility maturing on July 1, 2030. The undrawn facility enhances the company's operational and financial flexibility, though there are no immediate plans for its use.
The company anticipates Q2 2025 financial results to exceed previous guidance due to favorable member activity. Revenue, Adjusted net income, and Adjusted EBITDA are expected to surpass the ranges provided in May. Progyny will report detailed Q2 2025 results on August 7, 2025, after market close.
The company maintains its capital priorities, including potential stock repurchases, product portfolio expansion, investments in distribution channels, and strategic acquisitions.
Progyny (NASDAQ: PGNY), leader nelle soluzioni per la salute femminile e la costruzione della famiglia, ha ottenuto una nuova linea di credito revolving da 200 milioni di dollari con scadenza il 1° luglio 2030. Questa linea di credito non utilizzata migliora la flessibilità operativa e finanziaria dell'azienda, anche se al momento non sono previsti utilizzi immediati.
L'azienda prevede che i risultati finanziari del secondo trimestre 2025 supereranno le precedenti previsioni grazie a un'attività favorevole dei membri. Si stima che ricavi, utile netto rettificato e EBITDA rettificato supereranno le fasce indicate a maggio. Progyny comunicherà i dettagli dei risultati del secondo trimestre 2025 il 7 agosto 2025, dopo la chiusura del mercato.
L'azienda conferma le sue priorità di capitale, che includono potenziali riacquisti di azioni, espansione del portafoglio prodotti, investimenti nei canali distributivi e acquisizioni strategiche.
Progyny (NASDAQ: PGNY), líder en soluciones para la salud femenina y la formación de familias, ha asegurado una nueva línea de crédito revolvente de 200 millones de dólares con vencimiento el 1 de julio de 2030. Esta línea no utilizada mejora la flexibilidad operativa y financiera de la compañía, aunque no hay planes inmediatos para su uso.
La empresa anticipa que los resultados financieros del segundo trimestre de 2025 superarán las previsiones anteriores debido a una actividad favorable de los miembros. Se espera que los ingresos, el ingreso neto ajustado y el EBITDA ajustado superen los rangos proporcionados en mayo. Progyny informará los resultados detallados del segundo trimestre de 2025 el 7 de agosto de 2025, después del cierre del mercado.
La compañía mantiene sus prioridades de capital, que incluyen posibles recompras de acciones, expansión del portafolio de productos, inversiones en canales de distribución y adquisiciones estratégicas.
Progyny (NASDAQ: PGNY)는 여성 건강 및 가족 형성 솔루션 분야의 선두주자로서 2030년 7월 1일 만기인 2억 달러 규모의 회전 신용 한도를 확보했습니다. 사용되지 않은 이 신용 한도는 회사의 운영 및 재무 유연성을 강화하지만, 현재 즉각적인 사용 계획은 없습니다.
회사는 회원 활동이 호조를 보임에 따라 2025년 2분기 재무 실적이 이전 예상치를 상회할 것으로 기대합니다. 매출, 조정 순이익 및 조정 EBITDA는 5월에 제시된 범위를 초과할 것으로 예상됩니다. Progyny는 2025년 8월 7일 장 마감 후 2분기 상세 실적을 발표할 예정입니다.
회사는 주식 재매입 가능성, 제품 포트폴리오 확장, 유통 채널 투자 및 전략적 인수를 포함한 자본 우선순위를 유지합니다.
Progyny (NASDAQ : PGNY), leader dans les solutions de santé féminine et de construction de famille, a obtenu une nouvelle ligne de crédit renouvelable de 200 millions de dollars arrivant à échéance le 1er juillet 2030. Cette facilité non utilisée renforce la flexibilité opérationnelle et financière de l'entreprise, bien qu'aucun projet d'utilisation immédiate ne soit prévu.
L'entreprise prévoit que les résultats financiers du deuxième trimestre 2025 dépasseront les prévisions précédentes grâce à une activité favorable des membres. Le chiffre d'affaires, le bénéfice net ajusté et l'EBITDA ajusté devraient dépasser les fourchettes communiquées en mai. Progyny publiera les résultats détaillés du deuxième trimestre 2025 le 7 août 2025, après la clôture du marché.
L'entreprise maintient ses priorités en matière de capital, incluant d'éventuels rachats d'actions, l'expansion du portefeuille de produits, des investissements dans les canaux de distribution et des acquisitions stratégiques.
Progyny (NASDAQ: PGNY), ein führendes Unternehmen im Bereich Frauengesundheit und Familiengründungslösungen, hat eine neue revolvierende Kreditfazilität in Höhe von 200 Millionen US-Dollar mit Fälligkeit am 1. Juli 2030 gesichert. Die ungenutzte Fazilität erhöht die operative und finanzielle Flexibilität des Unternehmens, obwohl derzeit keine unmittelbaren Verwendungspläne bestehen.
Das Unternehmen erwartet, dass die Finanzergebnisse für das zweite Quartal 2025 die bisherigen Prognosen übertreffen werden, bedingt durch eine günstige Mitgliederaktivität. Umsatz, bereinigter Nettogewinn und bereinigtes EBITDA sollen die im Mai angegebenen Spannen übersteigen. Progyny wird die detaillierten Ergebnisse für das zweite Quartal 2025 am 7. August 2025, nach Börsenschluss, veröffentlichen.
Das Unternehmen hält an seinen Kapitalprioritäten fest, darunter mögliche Aktienrückkäufe, Erweiterung des Produktportfolios, Investitionen in Vertriebskanäle und strategische Übernahmen.
- Secured new $200 million revolving credit facility extending until 2030
- Q2 2025 financial metrics expected to exceed previous guidance
- Strong member activity trends reported
- Maintains significant cash flow generation capability
- No immediate plans for utilizing the new credit facility
- Potential future dilution if acquisitions are pursued using facility funds
Insights
Progyny secures $200M credit facility and projects better-than-expected Q2 results, strengthening its financial position.
Progyny's announcement of a new
The timing of this credit arrangement appears opportunistic, with management citing "favorable market conditions" - likely referring to securing advantageous interest terms before potential rate changes. While currently undrawn, this facility provides Progyny with expanded flexibility for its stated capital allocation priorities: stock repurchases, product portfolio expansion, distribution channel investments, and strategic acquisitions.
More immediately significant is management's updated outlook for Q2 2025, indicating performance exceeding previous guidance ranges for revenue, Adjusted net income, and Adjusted EBITDA. This positive revision stems from favorable member activity pacing, suggesting stronger utilization of Progyny's fertility and women's health benefits than initially projected. This could indicate either higher-than-expected membership growth or increased service utilization among existing members.
For investors, this announcement represents a dual positive: enhanced financial flexibility through the credit facility and stronger near-term operational performance. The credit facility particularly strengthens Progyny's ability to pursue growth opportunities in the expanding fertility benefits market while maintaining financial stability. The company continues to demonstrate operational execution in its specialized healthcare benefits segment, with member engagement trending positively.
Operational and Financial Flexibility Enhanced Through New Credit Facility
Second Quarter Results Anticipated to be Slightly Above Previously Provided Financial Guidance
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced that it has entered into a revolving credit facility (the “revolver” or the “facility”) which makes available to the Company up to
“At this stage of our growth, entering into a facility is an appropriate next step to further enhance our strong financial profile and extend our market leadership, and with the favorable market conditions, we felt this was an opportune time for us to transact,” said Pete Anevski, Chief Executive Officer of Progyny.
The revolver is undrawn, and the Company has no planned use for the facility at this time. The Company’s capital priorities, which include the evaluation of stock repurchases, the expansion of its product portfolio, investments in new distribution channels, and select acquisitions, remain unchanged.
The Company also announced today that it expects its financial results for the quarterly period ending June 30, 2025, to be slightly better than the guidance ranges it provided during its first quarter earnings call.
“As the second quarter progressed, we were pleased to see that member activity has paced favorably as compared to our guidance,” continued Anevski. “Accordingly, we now expect second quarter results for revenue, Adjusted net income and Adjusted EBITDA to be slightly above the ranges that we provided in May.”
The company will report its financial results for the quarterly period ended June 30, 2025, after the close of the market on Thursday, August 7, 2025.
The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.
Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio replay of the call will be available through Thursday, August 14, 2025, and may be accessed by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international participants) with the passcode 265484.
A live webcast and archive of the call will be available from the Events and Presentations section of the company’s website at http://investors.progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our financial outlook for the second quarter and full year 2025, including the impact of our sales season and client launches; our anticipated number of clients and covered lives for 2025; our expected utilization rates and mix; the demand for our solutions; our expectations for our selling season for 2026 launches; our positioning to successfully manage economic uncertainty on our business; the timing of client decisions; our ability to retain existing clients and acquire new clients; and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information. The words “anticipates,” “assumes,” “believe,” “contemplate,” “continues, ” “could,” “estimates,” “expects,” “future,” “intends,” “may,” “plans,” “predict,” “potential,” “project,” “seeks,” “should,” “target,” “will,” and the negative of these or similar expressions and phrases are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions.
Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward- looking statements. These risks include, without limitation, failure to meet our publicly announced guidance or other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability; unfavorable conditions in our industry or the United States economy; our limited operating history and the difficulty in predicting our future results of operations; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes or developments in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our vendors; a significant change in the utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our marketing and sales capabilities; the rate of growth of our future revenue; the accuracy of the estimates and assumptions we use to determine the size of target markets; our ability to successfully manage our growth; reductions in employee benefits spending; seasonal fluctuations in our sales; the adoption of new solutions and services by our clients or members; our ability to innovate and develop new offerings; our ability to adapt and respond to the changing medical landscape, regulations, and client needs, requirements or preferences; our ability to maintain and enhance our brand; our ability to attract and retain members of our management team, key employees, or other qualified personnel; risks related to any litigation against us; our ability to maintain our Center of Excellence network of healthcare providers; our strategic relationships with and monitoring of third parties; our ability to maintain our pharmacy distribution network if there is a disruption to our network or its associated supply chains; our relationship with key pharmacy program partners or any decline in rebates provided by them; our ability to maintain our relationships with benefits consultants; exposure to credit risk from our members; risks related to government regulation; risks related to our business with government entities; our ability to protect our intellectual property rights; risks related to acquisitions, strategic investments, or partnerships; federal tax reform and changes to our effective tax rate; the imposition of state and local state taxes; our ability to utilize a portion of our net operating loss or research tax credit carryforwards; our ability to develop or maintain effective internal control over financial reporting; and our ability to adapt and respond to the changing SEC or stakeholder expectations regarding environmental, social and governance practices. For a detailed discussion of these and other risk factors, please refer to our filings with the Securities and Exchange Commission (the “SEC”), including in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent reports that we file with the SEC, which are available at http://investors.progyny.com and on the SEC’s website at https://www.sec.gov.
Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this press release. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons.
Non-GAAP Financial Measures
In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), this press release includes the non-GAAP financial measure Adjusted EBITDA. Adjusted EBITDA is a supplemental financial measure that is not required by, or presented in accordance with, GAAP. We believe that this non-GAAP measure, when taken together with our GAAP financial results, provides meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA is helpful to our investors as it is used by management in assessing the health of our business, determining incentive compensation, evaluating our operating performance, and for internal planning and forecasting purposes.
Adjusted EBITDA is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Some of the limitations of Adjusted EBITDA include: (1) it does not properly reflect capital commitments to be paid in the future; (2) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures; (3) it does not consider the impact of stock-based compensation expense; (4) it does not reflect other non-operating income and expenses, including interest and other income, net; and (5) it does not reflect tax payments that may represent a reduction in cash available to us. In addition, Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate such measures in the same manner as we calculate Adjusted EBITDA, limiting its usefulness as a comparative measure. Because of these limitations, when evaluating our performance, you should consider Adjusted EBITDA alongside other financial performance measures, including our net income and our other GAAP results.
We calculate Adjusted EBITDA as net income, adjusted to exclude depreciation and amortization; stock-based compensation expense; interest and other income, net; and provision for income taxes.
For Further Information, Please Contact:
Investors:
James Hart investors@progyny.com
Media:
Alexis Ford media@progyny.com
FAQ
What is the size and term of PGNY's new revolving credit facility?
How will Progyny use the new credit facility funds?
When will Progyny (PGNY) report Q2 2025 earnings?
What are Progyny's capital allocation priorities for 2025?
How is Progyny's Q2 2025 performance tracking against guidance?
